11 results about "Resistance mutation" patented technology

The invention provides a molecular interaction network protection system based on structural biology and an optimization method thereof, and relates to the technical field of biotechnology and molecular engineering.The molecular interaction network protection system comprises a USAG-1 protein binding domain, and the USAG-1 protein binding domain comprises a Glu32-Arg58-Ser76 hydrogen bond network and a Phe41 / Trp65 / Leu83 hydrophobic core; the MMP-9 cleavage site mutant is used for carrying out 20 substitutions from D to N / V / A in the PLGLA sequence, and is combined with G52S mutation; the ellipticity of the CD spectrum of the RGD peptide at 222nm is less than or equal to-15 mdeg, and the RGD peptide comprises a salt bridge at the i / i + 4 position. The USAG-1 protein binding domain also comprises an Asn45 carbohydrate chain, and the molecular weight of the Asn45 carbohydrate chain is 500 to 2000 Da. The phi angle of the RGD peptide is-57 + / -5 degrees, and the psi angle of the RGD peptide is-47 + / -5 degrees. According to the invention, through a multi-dimensional structure locking strategy, while the functional activity of biomolecules is maintained, accurate control of alpha-helical conformation is realized, a resistance mutation library is constructed, and the fundamental contradiction of stability-activity imbalance, conformation control misalignment and single-point mutation drug resistance in the traditional technology is thoroughly solved.

This invention relates to a primer set and method for high-throughput assessment of drug resistance levels in rodent populations. The invention provides a set of universal degenerate primers for amplifying the Vkorc1 gene in multiple rodent species. The primer set includes primers for amplifying exon 1, exon 2, and exon 3 of the Vkorc1 gene, respectively. By designing universal degenerate primers and coupling them with next-generation sequencing technology, this invention can simultaneously amplify the Vkorc1 gene coding region of at least 15 rodent species across genera and families. This significantly improves the species universality and detection throughput of rodent drug resistance monitoring, reduces the cost of large-scale screening, overcomes the limitation of Sanger sequencing in accurately analyzing heterozygotes with insertions and deletions, and enhances the ability to discover new resistance mutations. It provides a standardized and low-cost technical solution for efficient assessment of rodent drug resistance.

This invention discloses a primer set for amplifying a novel HCV subtype 6xp and a primer set for detecting drug resistance mutations. The primer set for amplifying the novel HCV subtype 6xp includes nested PCR primers for amplifying the full length of the novel HCV subtype 6xp, while the primer set for detecting drug resistance mutations is a set of primers targeting drug resistance mutation sites in the three functional regions of NS3, NS5A, and NS5B. The primer set provided by this invention has high specificity and high amplification efficiency, enabling specific amplification of the entire genome of the novel HCV subtype 6xp and accurate detection of drug resistance mutation sites in the three functional regions. It is suitable for clinical diagnosis, antiviral treatment guidance, epidemiological surveys, and viral evolution research of this subtype, and has significant clinical application value and scientific research significance.

The present disclosure is based on methods for determining susceptibility of a human immunodeficiency virus type-1 (HIV-1) to one or more drugs. The present disclosure is also based on methods of performing drug resistance testing in a subject with HIV-1 or suspected of or having an HIV-1 infection. The present disclosure also relates to primers useful in these methods, and kits and articles of manufacture comprising the primers.

To provide new SERDs to treat cancers as well as mutations due to emerging resistance.SOLUTION: The present invention provides a novel selective estrogen receptor degrader (SERD) of the following formula (where either R1 or R2 is independently selected from Cl, F, -CF3, or -CH3, and the other is hydrogen), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof, and methods for use thereof.SELECTED DRAWING: None

Cell-stored barcoded viral protein libraries with are described. The libraries can be used to map resistance mutations to therapeutic treatments. The libraries include features that allow efficient collection and assessment of informative data, obviating many bottlenecks of previous approaches.

Cell-stored barcoded viral protein deep mutational scanning libraries are described. The libraries can be used to map resistance mutations to therapeutic treatments. The libraries can be used to predict viruses that become resistant to therapeutic compounds and / or may more easily evolve to infect new species. The libraries can also be used to more safely study dangerous viruses that normally require high safety biocontainment facilities. The libraries include features that allow efficient collection and assessment of informative data, obviating many bottlenecks of previous approaches.

The invention relates to the technical field of etoxazole resistance monitoring, in particular to application of a resistance gene haplotype CHS1-mut2 to accurate monitoring of etoxazole resistance. The nucleotide sequence table of the haplotype CHS1-mut2 is as shown in SEQ ID No 1. According to the application of the resistance gene haplotype CHS1-mut2 in accurately monitoring the etoxazole resistance provided by the invention, whether etoxazole has a good mite killing effect when facing tetranychus urticae or not can be detected by detecting the resistance mutation frequency of a medicament to etoxazole.

The invention discloses a one-tube detection method and kit for resistance mutation of a weed herbicide target gene based on combination of CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (Clustered Regularly Interspaced Short Palindromic Repeats) and LAMP (Loop-Mediated Isothermal Amplification), and the rapid detection of resistance mutation of sites such as 1999, 2027 and 2041 of an ACCase gene is realized by integrally integrating a CRISPR / Cas system specific recognition cutting technology and an LAMP efficient amplification technology. The detection lower limit of the technology reaches 1%, homozygous / heterozygous mutation typing can be completed within 60 minutes, the method is suitable for large-scale resistance screening in fields, and key technical support is provided for precise pesticide application and weed resistance management.

Methods to create barcoded influenza viruses without disrupting the function of the viral proteins and the proper packaging of the viral genome segments are described. The barcoded influenza viruses can be used within deep mutational scanning libraries to map influenza resistance mutations to therapeutic treatments. The libraries can also be used to predict influenza strains that may become resistant to therapeutic treatments and / or more easily evolve to infect new species.

This invention belongs to the field of molecular biology detection technology, and provides a primer composition, gDNA, probe, and method for detecting amino acid mutation sites in ALS of Amaranthus retroflexus. This invention is the first to construct a method for detecting multiple resistance mutations at multiple sites based on the synergistic effect of multiplex PCR and PfAgo. Through multiplex PCR amplification and PfAgo specific recognition and cleavage, it achieves simultaneous detection and mutation type identification of multiple resistance target sites in the ALS gene of Amaranthus retroflexus. Based on the multiple constraint mechanism of multiplex PCR amplification, PfAgo guided sequence recognition, and fluorescent probe cleavage, it achieves stepwise identification and verification of target sites, exhibiting excellent specificity, sensitivity, and robustness, reducing the risk of false positives, ensuring accurate and reliable results, and requiring no standards for interpretation. It is suitable for rapid and simultaneous multi-site detection of resistance to ALS inhibitors in Amaranthus retroflexus in the field, is simple to operate, and has low cost, providing technical support for resistance monitoring and precision herbicide management.